CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome	Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome	Active, not recruiting	Phase 1	2026-04-14		NCT03572764

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Jazz Pharmaceuticals	60
Washington University School of Medicine	475

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Fred Hutchinson Cancer Research Center	Seattle	United States	71
Moffitt Cancer Center	Tampa	United States	523
Washington University School of Medicine	St Louis	United States	895

Clinical trials